Key Questions: THE BEST FIRST LINE (III)
•
The monoclonal antibodies shownto improve of clinical outcome when
combined with polichemotherapy in the first line setting (EVIDENCE LEVEL IB)
Cmab-QT
Bv-QT
OS KRASwt 29,9 m
29,0 m
PFS KRASwt 10,8 m
10,4 m
OS RASwt 32,0 m
31,2 m
P=.34
P=.55
P=.40
No interaction with the non-different
OS with any type of chemotherapy
FOLFOX: 73%; FOLFIRI: 27%
37
